Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of landiolol hydrochloride, an ultra-short-acting β1-blocker

Drugs in R and D

Volumn 6, Issue 6, 2005, Pages 385-394

  Takahata, Takenori ^a   Yasui Furukori, Norio ^a   Sakamoto, Juichi ^a   Suto, Koji ^b   Suto, Toshiyuki ^a   Tateishi, Tomonori ^a   Munakata, Akihiro ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b Hirosaki City Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; INDOCYANINE GREEN; LANDIOLOL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BRADYCARDIA; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; CLINICAL LABORATORY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; FEVER; GEOMETRY; HEART RATE; HUMAN; HYPOTENSION; INFUSION PUMP; LABORATORY TEST; LEG CRAMP; LIVER DYSFUNCTION; MALE; PATIENT MONITORING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; URINALYSIS; VENOUS BLOOD;

ADRENERGIC BETA-ANTAGONISTS; AGED; FEMALE; HEART RATE; HUMANS; INFUSIONS, INTRAVENOUS; LIVER DISEASES; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MORPHOLINES; RECEPTORS, ADRENERGIC, BETA-1; UREA;

EID: 27744527587     PISSN: 11745886     EISSN: 11745886     Source Type: Journal    
DOI: 10.2165/00126839-200506060-00006     Document Type: Article

References (12)

1. Iguchi S, Iwamura H, Nishizaki M, et al. Development of a highly cardioselective ultra short-acting β-blocker, ONO-1101. Chem Pharm Bull 1992; 40: 1462-9
2. 1-blocking agent in healthy volunteers (in Japanese). Rinsho Iyaku 2000; 16: 1531-56
3. Kitamura A, Sakamoto A, Inoue T, et al. Efficacy of an ultrashort-acting β-adrenoceptor blocker (ONO-1101) in attenuat-ing cardiovascular responses to endotracheal intubation. Eur J Clin Pharmacol 1997; 51: 467-71
4. Atarashi H, Kuruma A, Yashima M, et al. Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting β-blocker, in patients with cardiac arrhythmias. Clin Pharmacol Ther 2000; 68: 143-50
5. US Food and Drug Administration: Guidance for industry. Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. Rockville (MD): US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, 2003
6. 1 blocker ONO-1101 (3): metabolism and protein binding (in Japanese). Drug Metab Pharmacokinet 1997; 12: 31-41
7. Morgan DJ, McLean AJ. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease: an update. Clin Pharmacokinet 1995; 29: 370-91
8. Thomson PD, Melmon KL, Richardson JA, et al. Lidocaine pharmacokinetics in advanced heart failure, liver disease and renal failure in humans. Ann Intern Med 1973; 78: 499-508
9. Crouthamel WG. The effect of congestive heart failure on quinidine pharmacokinetics. Am Heart J 1975; 90: 335-9
10. Koch-Weser J, Klein SW. Procainamide dosage schedules, plasma concentrations, and clinical effects. JAMA 1971; 215: 1454-60
11. 14C]-octanoate in cirrhosis of the liver and hepatic encephalopathy. J Lab Clin Med 1978; 91: 223-7
12. Shrestha R, McKinley C, Showalter R, et al. Quantitative liver function tests define the functional severity of liver disease in early-stage cirrhosis. Liver Transpl Surg 1997; 3: 166-73